Table 1.

Patient characteristics

Patient	Patient no.	Age, y	Sex, P/D	Disease status at SCT	DF8, m	T-cell chimerism D30	Myeloid chimerism D30
CML
	Pt1	45	M/M	CML CP	75 m	100	100
	Pt2	40	M/M	CML AP	143 m	N/A	N/A
	Pt3	41	M/F	CMLCP	66 rn	N/A	N/A
	Pt4	40	F/M	AML CR2	Rel, 7 m	94	100
	Pt5	33	F/F	CML CP	111 m	N/A	N/A
	Pt6	25	M/F	CML CP	100 m	59	100
	Pt7	31	M/M	CML-CP2	Died Rel, 50 m	N/A	N/A
	Pt8	36	F/M	CML CP	117 m	N/A	N/A
	Pt9	28	M/M	CML CP	Died Rel	56	100
	PtIO	45	M/F	CML BC	Died Rel	100	100
	Pt11	46	F/F	CML CP	131 m	100	100
	Pt12	33	M/M	CML CP	128 m	N/A	N/A
	Pt13	19	M/M	CML CP	122 m	N/A	N/A
ALL
	Pt14	27	F/F	ALL 3rd rel	Died Rel 11 m	38	97
	Pt15	10	F/F	ALL CR2	132 m	N/A	N/A
	Pt16	33	F/M	ALL CR2	Died Rel 9 m	36	100
	Pt17	22	F/F	ALL CR2	97 m	100	100
	Pt18	25	M/M	ALL ref	Died Rel 9 m
	Pt19	20	M/M	ALL CR2	73 m	87	100
	Pt20	18	F/M	ALL CR2	Died Rel 3 m	100	100
	Pt21	33	F/F	ALL rel	Died Rel 13 m	100	100
	Pt22	42	F/F	ALL CR2	49 m
Solid tumor
	Pt23	27	M/M	Sarcoma	PD, 8 m	N/A	N/A
	Pt24	37	F/F	Esoph Ca	PD, 18 m	N/A	N/A
	Pt25	37	M/F	Adenoca	PD, 7 m	N/A	N/A
	Pt26	28	F/M	Sarcoma	PD,4 m	N/A	N/A
	Pt27	44	F/F	Colon ca	PD, 8 m	N/A	N/A

CML chronic myeloid leukemia, ALL acute lymphoblastic leukemia, y year, Pt patient, D donor, M male, F female, CP chronic phase, AP accelerated phase, rel relapse, CR complete remission, ref refractory, Esoph Ca esophageal carcinoma, adenoca adenocarcinoma, m month, PD progressive disease, D day 30, N/A not available; Chimerism (%)